Acadia Pharma (ACAD)
28.02
+0.16 (0.57%)
Upcoming Events
Latest Headlines
Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
September 3, 2026 6:44 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley
August 25, 2026 8:30 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
August 25, 2026 6:57 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $40 at Citi
August 25, 2026 5:02 AM - StreetInsider
EU approves Acadia's trofinetide for Rett syndrome treatment
August 24, 2026 6:10 AM - StreetInsider
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
August 24, 2026 3:01 AM - BizWire
Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
August 17, 2026 6:50 AM - StreetInsider
Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
August 13, 2026 6:48 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $27 at Morgan Stanley
August 10, 2026 8:35 AM - StreetInsider
Form 4 ACADIA PHARMACEUTICALS For: Aug 05 Filed by: Schneyer Mark C.
August 7, 2026 6:00 PM - SEC Filing
Form SCHEDULE 13G ACADIA PHARMACEUTICALS Filed by: STATE STREET CORP
August 7, 2026 8:21 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
August 6, 2026 6:56 AM - StreetInsider
Form 144 ACADIA PHARMACEUTICALS Filed by: Schneyer Mark C.
August 5, 2026 4:50 PM - SEC Filing
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales'
August 5, 2026 7:44 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer
August 5, 2026 6:33 AM - StreetInsider
Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30
August 5, 2026 6:02 AM - SEC Filing
Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Citizens: Remains a Top Pick
August 5, 2026 4:07 AM - StreetInsider
Acadia Pharma (ACAD) Tops Q2 EPS by 12c ; Offers Guidance
August 5, 2026 12:52 AM - StreetInsider
Form 8-K ACADIA PHARMACEUTICALS For: Aug 04
August 4, 2026 4:18 PM - SEC Filing
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 4, 2026 4:05 PM - BizWire
Form 4 ACADIA PHARMACEUTICALS For: Jul 29 Filed by: Thompson Elizabeth H.Z.
July 31, 2026 6:00 PM - SEC Filing
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 30, 2026 5:57 PM - BizWire
Acadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities
July 29, 2026 5:19 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $36 at BMO Capital
July 21, 2026 7:36 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Stifel
July 20, 2026 4:25 PM - StreetInsider
Mizuho n Acadia Pharmaceuticals (ACAD): 'we view risk/reward as skewed significantly to the upside'
July 20, 2026 12:25 PM - StreetInsider
FDA grants fast track status to Acadia drug for Alzheimer's psychosis
July 20, 2026 9:05 AM - StreetInsider
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
July 20, 2026 9:05 AM - BizWire
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
July 15, 2026 4:05 PM - BizWire
Acadia Pharmaceuticals (ACAD) PT Raised to $36 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
July 6, 2026 9:04 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
June 30, 2026 6:44 AM - StreetInsider
Form 4 ACADIA PHARMACEUTICALS For: Jun 26 Filed by: Kihara James
June 29, 2026 6:00 PM - SEC Filing
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at Deutsche Bank
June 29, 2026 7:20 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Canaccord
June 29, 2026 6:49 AM - StreetInsider
Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
June 29, 2026 6:41 AM - StreetInsider
Acadia Pharma (ACAD) call put ratio 6.8 calls to 1 put with a focus on July 25 calls
June 29, 2026 6:03 AM - StreetInsider
Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
June 29, 2026 3:57 AM - StreetInsider
Form 144 ACADIA PHARMACEUTICALS Filed by: Kihara James
June 26, 2026 3:10 PM - SEC Filing
Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
June 26, 2026 12:33 PM - StreetInsider
Baird Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
June 26, 2026 10:51 AM - StreetInsider
Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
June 26, 2026 8:09 AM - StreetInsider
EU panel backs Acadia's Rett syndrome drug trofinetide for approval
June 26, 2026 6:49 AM - StreetInsider
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
June 26, 2026 6:49 AM - BizWire
Form S-8 ACADIA PHARMACEUTICALS
June 10, 2026 4:06 PM - SEC Filing
Full Article List
